Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Research & Development (2018 - 2025)

Historic Research & Development for Pharma (IGC) over the last 8 years, with Q3 2025 value amounting to $1.6 million.

  • Pharma's Research & Development rose 7317.34% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 2066.28%. This contributed to the annual value of $3.7 million for FY2025, which is 263.16% down from last year.
  • Per Pharma's latest filing, its Research & Development stood at $1.6 million for Q3 2025, which was up 7317.34% from $851000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Research & Development registered a high of $1.6 million during Q3 2025, and its lowest value of $276000.0 during Q3 2021.
  • For the 5-year period, Pharma's Research & Development averaged around $847526.3, with its median value being $852000.0 (2024).
  • As far as peak fluctuations go, Pharma's Research & Development soared by 26916.17% in 2022, and later tumbled by 5685.32% in 2023.
  • Quarter analysis of 5 years shows Pharma's Research & Development stood at $377000.0 in 2021, then surged by 113.79% to $806000.0 in 2022, then rose by 12.03% to $903000.0 in 2023, then fell by 5.65% to $852000.0 in 2024, then soared by 86.38% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $851000.0 for Q2 2025, and $1.0 million during Q1 2025.